Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146706 | 0.82 | PTGER1 (0.40) | PTGER1PARP1PTGS2PTGS1CYP2C9 | |
| SCHEMBL13696734 | 0.77 | ACMSD (0.41) | NAPRTPTGER1ACMSDCYP2C9 | |
| SCHEMBL4154619 | 0.71 | PTGER1 (0.50) | PTGER1CYP2C9 | |
| SCHEMBL13696730 | 0.71 | PTGER1 (0.40) | PTGER1ACMSDPTGS2CYP2C9 | |
| SCHEMBL13697486 | 0.70 | MCL1 (0.46) | PTGER1CYP2C9 | |
| SCHEMBL4156359 | 0.69 | PTGER1 (0.52) | PTGER1CYP2C9 | |
| SCHEMBL4158942 | 0.69 | PTGER1 (0.43) | NAPRTPTGER1ACMSDCYP2C9CYP3A4 | |
| SCHEMBL14499166 | 0.69 | PTGER1 (0.72) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL4153413 | 0.69 | KDM4E (0.39) | PTGER1PTGS2CYP2C9 | |
| SCHEMBL13697213 | 0.68 | PTGER1 (0.58) | PTGER1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | NAPRT 4802/4885PTGER1 246/4885ACMSD 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.